Risks of blood transfusion

Critical Care Medicine

Volumn 31, Issue 12 SUPPL., 2003, Pages

  Goodnough, Lawrence T ^a,b  

^a BARNES JEWISH HOSPITAL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Blood risks; Blood transfusion; Leukoreduction; Transfusion related immunomodulation; Transfusion transmitted infections

Indexed keywords

BACTERIUM CONTAMINATION; BIBLIOGRAPHIC DATABASE; BIOSAFETY; BLOOD GROUP ABO INCOMPATIBILITY; BLOOD TRANSFUSION; ERROR; FOLLOW UP; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOMODULATION; INFECTION RISK; LANGUAGE; LUNG INJURY; MEDICAL LITERATURE; NONHUMAN; PATHOGENESIS; POSTTRANSFUSION HEPATITIS; PRIORITY JOURNAL; REVIEW; SCREENING TEST; THROMBOCYTE; VIRUS INFECTION; VIRUS TRANSMISSION; WEST NILE FLAVIVIRUS;

EID: 0346887091     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ccm.0000100124.50579.d9     Document Type: Review

References (124)

1. Aach RD, Szmuness W, Mosley JW, et al: Serum alanine aminotransferase of donors in relation to the risk of non-A, non-B hepatitis in recipients: The Transfusion-Transmitted Viruses Study. N Engl J Med 1981; 304:989-994
2. Schreiber GB, Busch MP, Kleinman SH, et al: The risk of transfusion-transmitted viral infections. N Engl J Med 1996; 334: 1685-1690
3. Lackritz EM, Satten GA, Aberlee-Grasse J, et al: Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. N Engl J Med 1995; 333:1721-1725
4. Vamvakas EC, Taswell HF: Long-term survival after blood transfusion. Transfusion 1994; 34:471-477
5. Goodnough LT, Brecher ME, Kanter MH, et al: Transfusion medicine. Part I: Blood transfusion. N Engl J Med 1999; 340: 438-447
6. Busch MP, Kleinman SH, Nemo GJ: Current and emerging infectious risks of blood transfusions. JAMA 2003; 289:959-962
7. Goodnough LT, Shander A, Brecher ME: Transfusion Medicine: Looking to the future. Lancet 2003; 361:161-169
8. Joint statement on acquired immune deficiency syndrome (AIDS) related to transfusion. Transfusion 1983; 23:87-88
9. Silvergleid AJ, Leparc GF, Schmidt PJ: Impact of explicit questions about high-risk activities on donor attitudes and donor referral patterns: Results in two community blood centers. Transfusion 1989; 29: 362-364
10. Petersen LR, Lackritz E, Lewis W, et al: The effectiveness of the confidential unit exclusion option. Transfusion 1994; 34:865-869
11. Busch MP, Young MJ, Samson SM, et al: Risk of human immunodeficiency virus (HIV) transmission by blood transfusions before the implementation of HIV-1 antibody screening. Transfusion 1991; 31:4-11
12. AuBuchon JP, Birkmeyer JD, Busch MF: Safety of the blood supply in the United States: Opportunities and controversies. Ann Intern Med 1997; 127:904-909
13. Selik RM, Ward JW, Buehler JW: Trends in transfusion-associated acquired immune deficiency syndrome in the United States, 1982-1991. Transfusion 1993; 33:890-893
14. Update: HIV-2 infection among blood and plasma donors - United States, June 1992-June 1995. MMWR 1995; 44:603-606
15. Stramer SL, Grasse JA, Brodsky JP, et al: US blood donor screening with p24 antigen (Ag): One year experience. Transfusion 1997; 37(Suppl):1S
16. Domen RE: Paid-versus-volunteer blood donation in the United States: A historical review. Trans Med Rev 1995; 9:53-59
17. Dodd RY: Adverse consequences of blood transfusion: Quantitative risk estimates. In: Blood Supply: Risks Perceptions, and Prospects for the Future. Nance ST (Ed). Bethesda, American Association of Blood Banks, 1994, pp 1-24
18. Stevens CE, Aach RD, Hollinger FB, et al: Hepatitis B virus antibody in blood donors and the occurrence of non-A, non-B hepatitis in transfusion recipients: An analysis of the transfusion-transmitted viruses study. Ann Intern Med 1984; 101:733-738
19. Alter HJ, Purcell RH, Shih JN, et al: Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A and non-B hepatitis. N Eng J Med 1989; 321: 1494-1500
20. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. USHHS. Morbidity Mortality Weekly Report Oct 16, 1998
21. Conry-Cantilena C, van Raden M, Gibble J, et al: Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C infection. N Engl J Med 1996; 334: 1691-1696
22. Tong MJ, El-Farra NS, Reikes AR, et al: Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463-1466
23. Delwart E, Kalmin N, Jones S, et al: First case of HIV transmission by an RNA-screened blood donation. 9th Conference on Retroviruses and Opportunistic Infections, Feb 24-28, 2002. http://www.retro-conference.org/2002/ Posters/13519.pdf
24. HIV-tainted blood infects two in Florida. http://www.cbsnews.com/stories/ 2002/07/ 19/health/main515694.shtml
25. da Silva, Cardoso M, Koerner K, et al: The first case of HCV seroconversion after 3 years of HCV NAT screening in Baden-Wurttemberg. Transfusion 2000; 40: 1422-1423
26. Red blood cell transfusions contaminated with Yersinia enterocolitica - United States, 1991-1996, and initiation of a national study to detect bacteria-associated transfusion reactions. MMWR 1997; 46: 553-555
27. Cookson ST, Arduino MJ, Aguero SM, et al: Yersinia entercolitica- contaminated red blood cells - An emerging threat to blood safety. 1996 Interscience Conference on Antimicrobial Agents and Chemotherapy. ABS: 2352
28. Yomtovian R, Lazarus HM, Goodnough LT, et al: A prospective microbiologic surveillance program to detect and prevent the transfusion of bacterially contaminated platelets. Transfusion 1993; 33:902-909
29. Leiby DA, Kerr KL, Campos JM, et al: A retrospective analysis of microbial contaminants in outdated random-donor platelets from multiple sites. Transfusion 1997; 37: 259-263
30. Goldman M, Blajchman MA: Blood product-associated bacterial sepsis. Transfus Med Rev 1991; 5:73-83
31. Bacterial contamination of blood components. Association Bulletin #96-6. AABB Faxnet, No 294, American Association of Blood Banks, August 1996
32. Jacobs MR, Palavecino E, Yomtovian R: Don't bug me: The problem of bacterial contamination of blood components-challenges and solutions. Transfusion 2001; 41: 1331-1334
33. Ness PM, Braine HG, King K, et al: Single donor platelets reduce the risk of septic transfusion reactions. Transfusion 2001; 41:857-861
34. Ollgaard M, Albjerg I, Georgen J: Monitoring of bacterial growth in platelet concentrates - One year's experience with the BactAlertTM System. Vox Sanguinis 1998; 74(Suppl 1):1126
35. Laan E, Tros C: Improved safety and extended shelf-life of leuco-depleted platelet concentrates by automated bacterial screening. Transfusion 1999; 39:5S
36. Vuetic D, Taseki J, Balint B, et al: The use of BacTAlert system for bacterial screening in platelet concentrates. Vox Sanguinis 2000; (Suppl 1):P371
37. McDonald CP, Roy A, Lowe P, et al: The first experience in the United Kingdom of the bacteriological screening of platelets to increase shelf life to 7 days. Vox Sanguinis 2000; (Suppl 1):P375
38. Brecher ME, Means N, Jere CS, et al: Evaluation of the BacT/ALERT 3D® Microbial Detection System for platelet bacterial contamination: An analysis of 15 contaminating organisms. Transfusion 2001; 41: 477-482
39. AuBuchon JP, Cooper LK, Leach MF, et al: Bacterial culture of platelet units and extension of storage to 7 days. Transfusion 2001; 41S:1S
40. Brecher ME, Holland PV, Pineda A, et al: Bacterial growth in inoculated platelets: Implications for bacterial detection and the extension of platelet storage. Transfusion 2000; 40:1308-1312
41. Lin L, Cook DN, Wiesehahn GP, et al: Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 1997; 37:423-435
42. Knutson F, Alfonso R, Dupuis K, et al: Photochemical inactivation of bacteria and HIV in buffy-coat-derived platelet concentrates under conditions that preserve in vitro platelet function. Vox Sanguinis 2000; 78: 209-216
43. Corash L, Behrman B, Rheinschmidt M, et al: Post-transfusion viability and tolerability of photochemically treated platelet concentrates. Blood 1997; 90:267a
44. McCullough J, Vesole D, Benjamin RJ, et al: Pathogen-inactivated platelets using Helinx™ technology are hemostatically effective in the thrombocytopenia patient. Blood 2001; 98:45a
45. Sayers MH, Anderson KC, Goodnough LT, et al: Reducing the risk for transfusion-transmitted cytomegalovirus infection. Ann Intern Med 1992; 116:55-62
46. Rubie H, Attal M, Campardou AM et al: Risk factors for cytomegalovirus in BMT recipients transfused exclusively with seronegative blood products. Bone Marrow Transplant 1993; 11:209
47. Bowden RA, Sayers M, Fluornoy N, et al: Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med 1986; 314:1006
48. Vig R, DiPersio JF, Venkatraman P, et al: Donor CMV serostatus has no impact on CMV viremia or disease when prophylactic granulocyte transfusions are given following allogeneic peripheral blood stem cell blood transplantation. Blood 2003; 101: 2067-2069
49. Wingard JR, Chen DYH, Burns WH, et al: Cytomegalovirus infection after autologous bone marrow transplantation with comparison to infection after allogeneic bone marrow transplantation. Blood 1988; 71:432
50. Verdonck LF, van der Linden JA, Bast BJEG, et al: Influence of cytomegalovirus-infections on the recovery of humoral immunity after autologous bone marrow transplant. Exp Hematol 1987; 15:864
51. Wingard JR, Sostrin MB, Vriessendorp HM, et al: Interstitial pneumonitis following autologous bone marrow transplantation. Transplantation 1988; 46:61
52. American Association of Blood Banks: Leukocyte reduction for the prevention of transfusion-transmitted cytomegalovirus (TT-CMV). AABB Bull 1997; 17:391
53. Holmberg LA, Boeckh M, Hooper H, et al: Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood 1999; 94:4029-4035
54. Bowden RA, Slichter SJ, Sayers M, et al: A comparison of filtered leukocyte reduced and cytomegalovirus (CMV)-seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1985; 86:3598
55. Ledent E, Berlin G: Inadequate white cell reduction from red cell concentrates by filtration. Transfusion 1994; 34:765
56. Landaw EM, Kanter M, Petz LD: Safety of filtered leukocyte-reduced blood products for the prevention of transfusion-associated cytomegalovirus infection. Blood 1996; 87: 4910-4919
57. Adler SP, Baggett J, McVoy M, et al: Transfusion-associated cytomegalovirus infections in seropositive cardiac patients. Lancet 1985; 1:743
58. VATS study shows no benefit of leukocyte reduction for HIV-infected patients. AABB Weekly Report 1999; 5:1-2
59. Nichols WG, Price TH, Gooley T, et al: Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood 2003; 101: 4195-4200
60. Blajchman MA, Goldman M, Freedman JJ, et al: Proceedings of a consensus conference: Prevention of post-transfusion CMV in the error of universal leukoreduction. Trans Med Rev 2001; 15:1-20
61. Luban NLC: Human parvoviruses: Implications for transfusion medicine. Transfusion 1994; 34:821-827
62. Gout O, Baulac M, Gessain A, et al: Rapid development of myelopathy after HTLV-I infection acquired by transfusion during cardiac transplantation. N Engl J Med 1990; 322:383-388
63. Kanno M, Nakamura S, Matsuda T: Adult T-cell leukemia with HTLV-I associated myelopathy after complete remission of acute myelogenous leukemia. N Eng J Med 1998; 338:333
64. Nahlen BL, Lobel HO, Cannon SE, et al: Reassessment of blood donor selection criteria for United States travelers to malarious areas. Transfusion 1991; 31:786-788
65. Guerrero IC, Weneger BG, Schultz MG: Transfusion malaria in the United States, 1972-1981. Ann Intern Med 1983; 99:221
66. Mungai M, Tegtmeier G, Chamberland M, et al: Transfusion-transmitted malaria in the United States from 1963 through 1999. N Engl J Med 2001; 344:1973-1978
67. Schmunis GA: Trypanosomo cruzi, the etiologic agent of Chagas' disease: Status in the blood supply in endemic and nonendemic countries. Transfusion 1991; 31: 547-557
68. Schmunis GA, Zueker F, Cruz JR, et al: Safety of blood supply for infectious disease in Latin American countries. Am J Trop Med Hug 2001; 65:924-930
69. Shulman IA, Appelman S, Saxena S, et al: Specific antibodies to Trupansoma Cruzi among blood donors in Los Angeles, California. Transfusion 1997; 37:727-731
70. Cimo PL, Luper WE, Scouroso MA: Transfusion-associated Chagas' disease in Texas: Report of a case. Tex Med J 1993; 89:48-50
71. CDC: Chagas disease after organ transplantation. United States, 2001. http://www.cdc.gov/mmwr/preview/mmwrhtm/ mm511093.htm
72. McQuiston JH, Childs JE, Chamberland ME, et al: Transmission of tick-borne agents of disease by blood transfusion: A review of known and potential risks in the United States. Transfusion 2000; 40:274-284
73. Brown P, Preece MA, Will RG: Friendly fire in medicine: Hormones, homografts, and Creutzfeldt-Jacob disease. Lancet 1992; 340:24-27
74. Dodd RY, Sullivan MT: Creutzfeldt-Jacob disease and transfusion safety: Tilting at icebergs? Transfusion 1998; 38:221-223
75. Revised preventative measures to reduce the possible risk of transmission of CJD and vCJD by blood and blood products. http:// www.fda.gov/cber/gdlins/cjdvcjd.htm
76. Bordin JO, Heddle NM, Blajchman MA: Biologic effects of leukocytes present in transfused cellular blood products. Blood 1994; 84:1703
77. Landers DF, Hill GE, Wong KC, et al: Blood transfusion-induced immunomodulation. Anesth Analg 1996; 82:187-204
78. Vamvakas EC, Dzik WH, Blajchman MA: Deleterious effects of transfusion-associated immunomodulation: Appraisal of the evidence and recommendations for prevention. In: Immunomodulatory Effects of Blood Transfusion. Vamvakas (Ed). Bethesda, AABB Press, 1999, pp 253-285
79. Lane TA, Anderson KC, Goodnough LT, et al: Leukocyte reduction in blood component therapy. Ann Intern Med 1992; 117: 151-162
80. British Committee for Standards in Haematology, Blood Transfusion Task Force: Guidelines on the clinical use of leukocyte-depleted blood components. Transfus Med 1998; 8:59-71
81. Brown P, Cervenakova L, McShane LM, et al: Further studies of blood infectivity in an experimental model of transmissible sponge for encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans. Transfusion 1999; 39:1169-1178
82. BPAC Recommends Universal Leukoreduction. AABB Newsbriefs 1998; 20:16
83. Goodnough LT: The case against universal leukoreduction (and for the practice of evidence-based medicine). Transfusion 2000; 40:1522-1527
84. National Blood Data Resource Center: Comprehensive report on blood collection and transfusion in the United States in 1999. Bethesda, 2001
85. Pall Corp: Demand leukocyte-depleted blood for more complete patient protection (advertisement). Ann Thor Surg 1995; 60: A20-A21
86. Menitove JE, McElligott MC, Aster RH: Febrile transfusion reaction: What blood component should be given next? Vox Sang 1982; 42:318-321
87. Chambers LA, Kruskall MS, Pacini DG, et al: Febrile reactions after platelet transfusion: The effect of single vs multiple donors. Transfusion 1990; 30:219-221
88. TRAP Study Group: Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997; 337:1861-1869
89. Goodnough LT, Riddell J, Lazarus H, et al: Prevalence of platelet transfusion reactions before and after implementation of leukocyte-depleted platelet concentrates by filtration. Vox Sang 1993; 65:103-107
90. Heddle NM, Kama L, Singer J, et al: The role of plasma in transfusion reactions. N Engl J Med 1994; 331:625-628
91. Shiba M, Tabdokoro K, Sawanobori M, et al: Activation of the contact system by filtration of platelet concentrates with a negatively charged white cell removal filter and measurement of venous blood bradykinin level in patients who received filtered platelets. Transfusion 1997; 37:457-462
92. Leukoreduction: The techniques used, their effectiveness and costs. Canadian coordinating office for health technology assessment (ECOHTA), 1998. See http://www.ecohta.ca
93. Uhlmann EJ, Isriggs E, Walher M, et al: Pre-storage universal leukoreduction of RBC does not affect the incidence of transfusion reactions. Transfusion 2001; 41: 997-1000
94. Dzik WH, Anderson SK, O'Neill EM, et al: A prospective, randomized clinical trial of universal WBC reduction. Transfusion 2002; 42:1114-1122
95. Hebert PC, Fergusson D, Blajchman MA, et al: Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions. JAMA 2003; 289:1993-1995
96. Corwin HL, AuBuchon JP: Is leukoreduction of blood components for everyone? JAMA 2003; 289:1941-1949
97. Isheda A, Hanaoa M, Wakui M, et al: Clinical factors influencing post transfusion platelet increment in patients undergoing hematopoietic progenitor cell transplantation. Transfusion 1998; 38:839-847
98. Bernstein SH, Vose JM, Fay JW, et al: A multicenter study of platelet recovery and utilization in patients after myeloblative therapy and hematopoietic stem cell transplantation. Blood 1998; 91:3509-3517
99. Goodnough LT, Kuter D, McCullough J, et al: Apheresis platelets: Emerging issues related to donor platelet count, apheresis platelet yield, and platelet transfusion dose. J Clin Apher 1998; 13:114-119
100. Opelz G, Terasaki PI: Improvement of kidney-graft survival with increased numbers of blood transfusions. N Engl J Med 1978; 299:799-803
101. Mowbray JF, Gibbins C, Liddell H, et al: Controlled trial of treatment of recurrent spontaneous abortion by immunization with paternal cells. Lancet 1985; 1:941
102. Blajchman MA: Transfusion-associated immunomodulation and universal white cell reduction: Are we putting the cart before the horse? Transfusion 1999; 39:667-670
103. Ober C, Karrison T, Odem RR, et. al: Mononuclear cell immunization in prevention of recurrent miscarriages: A randomized trial. Lancet 1999; 354:365-369
104. Vamvakas EC: Transfusion-associated cancer recurrence and postoperative infection: Meta-analysis of randomized, controlled clinical trials. Transfusion 1996; 36: 175-186
105. Heiss MM, Mempel W, Delanoff C, et al: Blood transfusion-modulated tumor recurrence: First results of a randomized study of autologous versus allogeneic blood transfusion in colorectal cancer surgery. J Clin Oncol 1994; 12:1859-1867
106. Busch OR, Hop WC, van Papendrecht H, et al: Blood transfusions and prognosis in colorectal cancer. N Engl J Med 1993; 328: 1372-1376
107. Houbiers JG, van de Watering LM, Hermans J, et al: Randomized controlled trial comparing transfusion of leukocyte-depleted or buffy-coat-depleted blood in surgery for colorectal cancer. Lancet 1994; 344: 573-578
108. van de Watering LMG, Hermans J, Houbiers JGA, et al: Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery: A randomized clinical trial. Circulation 1998; 97:562-568
109. Hattler BG, Madia C, Johnson C, et al: Risk stratification using the Society of Thoracic Surgeons program. Ann Thor Surg 1994; 58:1348-1352
110. Popovsky MA, Moore SB: Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion 1985; 25:573-577
111. Silliman CC, Paterson AJ, Dickey WO, et al: The association of biologically active lipids with the development of transfusion-related acute lung injury: A retrospective study. Transfusion 1997; 37: 719-726
112. Wallis JP, Lubenko A, Wells AW, et al: Single hospital experience of TRALI. Transfusion 2003; 43:1053-1059
113. Consultant Pathologists Group Committee: Blood transfusion accidents. BMJ 1953; 2:390-391
114. Linden JV, Wagner K, Voytovich AE, et al: Transfusion errors in New York State: An analysis of 10 years' experience. Transfusion 2001; 40:1207-1213
115. Williamson LM, Lowe S, Love E, et al: Serious hazards of transfusion. Initiative: Analysis of first two annual reports. BMJ 1999; 319:16-19
116. Sazama K: Reports of 355 transfusion-associated deaths: 1976 through 1985. Transfusion 1990; 30:583-590
117. Goldman M, Remy-Prince S, Trepanier A, et al: Autologous donation error rates in Canada. Transfusion 1997; 37:523-527
118. Noninfectious serious hazards of transfusion. Association Bulletin #01-4. Bethesda, American Association of Blood Bank, June 14, 2001
119. Sampathkuman P: West Nile virus: Epidemiology, clinical presentation, diagnosis, and prevention. Mayo Clin Proc 2003; 78: 1137-1156
120. www.cdc.gov/mmwr/preview/mmwrhtml/ mm52d918a1.htm
121. Peterson LR, Marfin AA: West Nile virus: a primer for the clinician. Ann Intern Med 2003; 137:173-179
122. Pealer LN, et al: Transmission of West Nile virus through blood transfusion in the United States in 2002. N Engl J Med 2003; 349:1236-1246
123. Biggerstaff BJ, Peterson LR: Estimated risk of transfusion of the West Nile virus through blood transfusion in the U.S., 2002. Transfusion 2003; 43:1053-1059
124. Corash L: Inactivation of viruses, bacteria, protozoa, and leukocytes in platelet concentrates: Current research perspectives. Transfus Med Rev 1999; 13:13-30